MX394089B - Nuevos derivados de xantina sustituidos. - Google Patents

Nuevos derivados de xantina sustituidos.

Info

Publication number
MX394089B
MX394089B MX2020000402A MX2020000402A MX394089B MX 394089 B MX394089 B MX 394089B MX 2020000402 A MX2020000402 A MX 2020000402A MX 2020000402 A MX2020000402 A MX 2020000402A MX 394089 B MX394089 B MX 394089B
Authority
MX
Mexico
Prior art keywords
xanthine derivatives
new replaced
replaced
new
derivatives
Prior art date
Application number
MX2020000402A
Other languages
English (en)
Spanish (es)
Other versions
MX2020000402A (es
Inventor
Achim Sauer
Bertrand L Chenard
Christian Eickmeier
Kai Gerlach
Stefan Just
Original Assignee
Boehringer Ingelheim Int
Hydra Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Hydra Biosciences Llc filed Critical Boehringer Ingelheim Int
Publication of MX2020000402A publication Critical patent/MX2020000402A/es
Publication of MX394089B publication Critical patent/MX394089B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2020000402A 2017-07-11 2018-07-06 Nuevos derivados de xantina sustituidos. MX394089B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 NEW SUBSTITUTED XANTHINE DERIVATIVES

Publications (2)

Publication Number Publication Date
MX2020000402A MX2020000402A (es) 2020-08-17
MX394089B true MX394089B (es) 2025-03-24

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000402A MX394089B (es) 2017-07-11 2018-07-06 Nuevos derivados de xantina sustituidos.

Country Status (32)

Country Link
US (1) US10329292B2 (cg-RX-API-DMAC7.html)
EP (1) EP3652176B1 (cg-RX-API-DMAC7.html)
JP (1) JP7114702B2 (cg-RX-API-DMAC7.html)
KR (1) KR102714554B1 (cg-RX-API-DMAC7.html)
CN (1) CN110997675B (cg-RX-API-DMAC7.html)
AR (1) AR112448A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018299824B2 (cg-RX-API-DMAC7.html)
CA (1) CA3066922A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000056A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019015102A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125014T1 (cg-RX-API-DMAC7.html)
DK (1) DK3652176T3 (cg-RX-API-DMAC7.html)
EA (1) EA039526B1 (cg-RX-API-DMAC7.html)
ES (1) ES2903268T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220029T1 (cg-RX-API-DMAC7.html)
HU (1) HUE057600T2 (cg-RX-API-DMAC7.html)
IL (1) IL271799B (cg-RX-API-DMAC7.html)
LT (1) LT3652176T (cg-RX-API-DMAC7.html)
MX (1) MX394089B (cg-RX-API-DMAC7.html)
MY (1) MY200797A (cg-RX-API-DMAC7.html)
PE (1) PE20200861A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020500079A1 (cg-RX-API-DMAC7.html)
PL (1) PL3652176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3652176T (cg-RX-API-DMAC7.html)
RS (1) RS62826B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410851B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201912168TA (cg-RX-API-DMAC7.html)
SI (1) SI3652176T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200013T1 (cg-RX-API-DMAC7.html)
TW (1) TWI801398B (cg-RX-API-DMAC7.html)
UA (1) UA124793C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019011802A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019231208B2 (en) * 2018-03-05 2025-01-23 Gfb (Abc), Llc Imidazodiazepinediones and methods of use thereof
US12291532B2 (en) 2018-12-12 2025-05-06 Boehringer Ingelheim International Gmbh Substituted xanthines as modulators of TRPC5 activity
IL283768B2 (en) * 2018-12-12 2024-05-01 Boehringer Ingelheim Int Xanthine histories are transmuted
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Gfb (Abc), Llc Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
KR20250141831A (ko) 2023-02-08 2025-09-29 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 잔틴계 화합물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
MX370372B (es) * 2013-03-15 2019-12-11 Hydra Biosciences Inc Xantinas sustituidas y metodos de uso de las mismas.
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位a1離子通道
EP3180340B1 (en) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体
EP3194367B1 (en) 2014-09-17 2021-08-18 Boehringer Ingelheim International GmbH Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Also Published As

Publication number Publication date
EP3652176A1 (en) 2020-05-20
PT3652176T (pt) 2022-01-13
US20190016722A1 (en) 2019-01-17
EA039526B1 (ru) 2022-02-07
PE20200861A1 (es) 2020-08-25
TWI801398B (zh) 2023-05-11
KR20200030048A (ko) 2020-03-19
CO2019015102A2 (es) 2020-05-15
BR112019025611A2 (pt) 2020-06-16
EP3652176B1 (en) 2021-12-15
HUE057600T2 (hu) 2022-05-28
SI3652176T1 (sl) 2022-04-29
US10329292B2 (en) 2019-06-25
HRP20220029T1 (hr) 2022-04-15
CN110997675A (zh) 2020-04-10
AR112448A1 (es) 2019-10-30
JP7114702B2 (ja) 2022-08-08
RS62826B1 (sr) 2022-02-28
MY200797A (en) 2024-01-16
SA519410851B1 (ar) 2023-02-26
PL3652176T3 (pl) 2022-04-04
WO2019011802A1 (en) 2019-01-17
UA124793C2 (uk) 2021-11-17
DK3652176T3 (da) 2022-01-17
PH12020500079A1 (en) 2020-10-05
SMT202200013T1 (it) 2022-03-21
MX2020000402A (es) 2020-08-17
CL2020000056A1 (es) 2020-06-12
EA202090270A1 (ru) 2020-04-24
LT3652176T (lt) 2022-02-25
CA3066922A1 (en) 2019-01-17
KR102714554B1 (ko) 2024-10-10
CY1125014T1 (el) 2023-03-24
ES2903268T3 (es) 2022-03-31
AU2018299824B2 (en) 2022-06-16
CN110997675B (zh) 2022-06-07
IL271799A (en) 2020-02-27
JP2020526591A (ja) 2020-08-31
AU2018299824A1 (en) 2019-12-19
NZ759728A (en) 2024-11-29
IL271799B (en) 2022-08-01
SG11201912168TA (en) 2020-01-30
TW201908318A (zh) 2019-03-01

Similar Documents

Publication Publication Date Title
MX2017001512A (es) Compuestos activos hacia bromodominios.
CO2019015102A2 (es) Nuevos derivados de xantina sustituidos
AR121273A2 (es) Inhibidores enzimáticos para uso en medicina y composición farmacéutica que los comprende
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
SV2018005778A (es) Derivados aromaticos de sulfonamida
CL2016002269A1 (es) Moduladores alostéricos del núcleo proteico de la hepatitis b.
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CL2018003417A1 (es) Nuevos compuestos.
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
CL2021001509A1 (es) Derivados de xantina sustituida
MX2018005350A (es) Formulacion de combinacion de dosis fija, eflornitina y sulindaco.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
BR112016028081A2 (pt) Novos compostos como agentes antituberculares
EA201990041A1 (ru) Композиции, содержащие тимолол, и их применение при лечении розацеа при местном применении